VIDEO: Duravyu for wet AMD to enter phase 3 pivotal trials in second half of 2024
Click Here to Manage Email Alerts
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Jay S. Duker, MD, of EyePoint Pharmaceuticals discusses lead product Duravyu.
Duravyu (formerly EYP-1901) is an intravitreal insert that delivers vorolanib, a tyrosine kinase inhibitor, and is under investigation for the treatment of wet age-related macular degeneration, diabetic macular edema and nonproliferative diabetic retinopathy. It is advancing into phase 3 pivotal trials in wet AMD, with patient dosing expected to begin later this year, Duker said.
“We’re really excited about the possibility of Duravyu acting as a maintenance therapy after an induction with an anti-VEGF agent in wet age-related macular degeneration,” he said. “That will enable patients and practitioners to have more flexibility with less visits and less injections.”
Collapse
Singh RP, et al. Retina World Congress unplugged: What’s new in wet AMD. Presented at: Retina World Congress; May 9-12, 2024; Fort Lauderdale, Florida.
Click Here to Manage Email Alerts